Spire Healthcare : NHS COVID-19 support

Regulatory Story
Go to market news section
Spire Healthcare Group PLC - SPI NHS COVID-19 support Released 07:00 13-Mar-2020

RNS Number : 0620G

Spire Healthcare Group PLC

13 March 2020

Spire Healthcare Group plc

('Spire Healthcare', 'the Company' or 'the Group')

NHS COVID-19 support

13 March 2020

Spire Healthcare (LSE: SPI), a leading UK independent hospital group, today announces that following a meeting with NHS England and representatives from across the private sector to discuss future COVID-19 planning, Spire Healthcare has been asked for, and has offered, its support to the NHS during this challenging time.

The exact nature, extent and the timing of this support is yet to be determined; in the meantime, we continue to offer a full service to our patients. We will update the market when further information is available.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

Spire Healthcare Cora McCallum, Head of Investor Relations	[phone]
Instinctif Partners Guy Scarborough Damian Reece	[phone] [phone]

Registered Office and Head Office:

Spire Healthcare Group plc

3 Dorset Rise

London

EC4Y 8EN

Registered number 09084066

About Spire Healthcare

Spire Healthcare is a leading independent hospital group in the United Kingdom, with 39 private hospitals and 8 clinics across England, Wales and Scotland.

Working in partnership with around 7,300 experienced consultants, Spire Healthcare delivered tailored, personalised care to approximately 810,000 in-patients and daycase patients in 2019, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom.

The Group's well located and scalable hospitals have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, consultants, the NHS, GPs and Private Medical Insurance ('PMI') providers. 85% of Spire Healthcare's hospitals are rated Good or Outstanding by the CQC (or the equivalent in Scotland and Wales).

Spire treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCJJMFTMTIBMLM

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2014London Stock Exchange plc. All rights reserved

NHS COVID-19 support - RNS